Back to All

Issue of Share Options/PDMR Shareholdings

6 April, 2021

Diaceutics PLC

(“Diaceutics” or the “Company”)

Issue of Share Options/PDMR Shareholdings

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issue of share options over ordinary shares of £0.002 each in the Company (“Share Options”) to certain Directors, members of the Company’s senior management team and other key staff, pursuant to the Company’s Employee Share Option Plan (“ESOP”). These awards are made in accordance with the Company’s long term incentive plan.

Share Options were granted as follows:


Number of Share Options granted

Total no. of ordinary shares under option post grant

% of existing issued share capital

Effective Grant date

Peter Keeling, CEO




1 April 2021

Philip White, CFO




1 April 2021

Ryan Keeling, CIO




1 April 2021

Damian Thornton, COO and PDMR




1 April 2021

Jordan Clark, CCO and PDMR




1 April 2021

Susanne Munksted, PDMR




1 April 2021

Other employees (36 persons)




   1 April 2021

The Share Options vest on a sliding scale up to 100%, after three years from the date of grant (the “Performance Period”), subject to the satisfaction of certain performance criteria. The performance criteria is based upon the growth in Total Shareholder Return, measured using the average mid-market closing share price in the month immediately before the end of the Performance Period, plus any dividends declared and paid during the Performance Period. The growth in TSR will be measured against a base share price of 102.67p, being the average mid-market closing share price in the three days prior to 1 April 2021, when the options were issued. The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the shares.

Following this grant, the total number of share options outstanding in the Company is 2,016,687, representing approximately 2.4% of its current issued share capital of 84,063,923.


Diaceutics PLC

Peter Keeling, Chief Executive Officer

via Walbrook PR

Philip White, Chief Financial Officer


Cenkos Securities plc (Nominated adviser and broker)

+44 (0)207 397 8900

Callum Davidson / Giles Balleny

Michael Johnson (Sales)


Walbrook PR

Tel: +44 (0)20 7933 8780 or [email protected]

Anna Dunphy

Mob: +44 (0)7876 741 001

Paul McManus

Mob: +44 (0)7980 541 893

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX – our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. Diaceutics has worked on every precision medicine brought to market and provides solutions to 36 of the world’s leading pharmaceutical companies. DXRX – the Diagnostic Network ® provides unrivalled access to deep analysis and insights from the world’s largest repository of diagnostic testing data on one secure platform.

About DXRX – The Diagnostic Network®

DXRX is Diaceutics’ proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.